Physician profile
Smyrne Balan-Louis
NPI 1841886546
$9,248.16
in general payments reported to CMS, 2019-2025
56 companies · $3,867 in 2025
The $3,867 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $74.04 · 2023: $1,765 · 2024: $3,542 · 2025: $3,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,242 · Education: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,241.78 |
| Education | $932.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,078.78 | 2023-2025 | Rybrevant, Carvykti, Darzalex |
| Celgene Corporation | $726.08 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Astrazeneca Pharmaceuticals Lp | $547.53 | 2023-2025 | Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $535.84 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astellas Pharma US INC | $504.14 | 2023-2025 | Xtandi, Vyloy, Xospata |
| Bayer Healthcare Pharmaceuticals INC. | $412.75 | 2024-2025 | |
| Incyte Corporation | $396.56 | 2024-2025 | Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $362.92 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $306.93 | 2024-2025 | Ultomiris |
| Pfizer INC. | $303.49 | 2023-2025 | |
| Daiichi Sankyo INC. | $288.73 | 2024-2025 | Enhertu, Datroway |
| Abbvie INC. | $276.69 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $276.11 | 2023-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Lilly USA, LLC | $233.57 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Tersera Therapeutics LLC | $199.25 | 2023-2025 | Zoladex |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $192.48 | 2023-2025 | Phesgo, Tecentriq, Venclexta |
| Glaxosmithkline, LLC. | $185.65 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Sobi, INC | $181.13 | 2024-2025 | |
| Eisai INC. | $176.43 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $164.33 | 2024-2025 | Xpovio |
| Seagen INC. | $145.91 | 2023-2025 | Tukysa, Tivdak |
| Exelixis INC. | $139.91 | 2023-2024 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $105.59 | 2024-2025 | Onivyde, Somatuline Depot |
| Beigene USA, INC. | $103.89 | 2023-2025 | Brukinsa, Tevimbra |
| Jazz Pharmaceuticals INC. | $94.46 | 2024-2025 | |
| Geron Corporation | $93.60 | 2024-2025 | Rytelo |
| Mirati Therapeutics, INC. | $88.57 | 2023-2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $85.04 | 2023-2025 | Libtayo, Lynozyfic |
| Adc Therapeutics America, INC. | $74.12 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $70.49 | 2025 | Tavalisse |
| Array Biopharma INC | $65.90 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Legend Biotech USA INC. | $65.05 | 2025 | Carvykti |
| Adaptive Biotechnologies Corporation | $62.94 | 2023-2025 | Clonoseq |
| Janssen Pharmaceuticals, INC | $59.30 | 2022-2025 | |
| Servier Pharmaceuticals LLC | $57.64 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $57.54 | 2024-2025 | Myrisk, Precisetumor |
| Deciphera Pharmaceuticals INC. | $54.19 | 2024-2025 | Qinlock, Romvimza |
| Genzyme Corporation | $50.62 | 2023-2024 | |
| Stemline Therapeutics INC. | $49.08 | 2023-2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $40.01 | 2024 | Monoferric, Cosela |
| Recordati_rare_diseases_inc. | $39.07 | 2023-2024 | Sylvant |
| Aveo Pharmaceuticals, INC. | $30.98 | 2023 | Fotivda |
| Emd Serono, INC. | $24.17 | 2024 | |
| Csl Behring | $22.98 | 2022 | |
| Kite Pharma, INC. | $21.72 | 2025 | Yescarta |
| Puma Biotechnology, INC. | $21.67 | 2025 | |
| Kyowa Kirin, INC. | $21.40 | 2023 | Poteligeo |
| Delcath Systems | $21.26 | 2025 | Hepzato Kit |
| Cumberland Pharmaceuticals, INC. | $20.53 | 2024 | Sancuso |
| Beone Medicines USA, INC. | $19.54 | 2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $18.54 | 2023 | Imbruvica, Epkinly |
| Pharmaessentia USA Corporation | $18.32 | 2025 | Besremi |
| Shield Therapeutics INC | $17.65 | 2024 | |
| Agios Pharmaceuticals, INC. | $15.70 | 2024 | Pyrukynd |
| Immunocore Limited | $13.75 | 2025 | Kimmtrak |
| Iovance Biotherapeutics, INC. | $7.64 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smyrne Balan-Louis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.